Ethicon Endo-Surgery has entered into a definitive agreement to acquire SurgRx, a privately held developer of the advanced bipolar tissue sealing system used in the EnSeal(R) family of devices. The acquisition will provide Ethicon Endo-Surgery with a new platform to complement its HARMONIC(R) line of ultrasonic medical devices that have been used to perform open and laparoscopic procedures worldwide. Terms of the agreement were not disclosed. The transaction is subject to customary clearances.

"Ethicon Endo-Surgery and SurgRx share a commitment to innovation for the surgeons and patients who depend on our products," said Karen Licitra, Company Group Chairman and Worldwide Franchise Chairman, Ethicon Endo-Surgery. "Together, the combination of HARMONIC(R) and EnSeal(R) technologies will position us to better address many different procedure needs."

"The acquisition has the potential to expand the global availability of the EnSeal(R) product line," said Rodney Perkins M.D., Chairman, Board of Directors, SurgRx. Dave Clapper, President & CEO, SurgRx added, "We are looking forward to joining forces with Ethicon Endo-Surgery to offer these complementary technologies to even more patients worldwide."
About SurgRx
SurgRx was founded in 2002 and is located in Redwood City, Calif. The EnSeal(R) family of devices combines high compression and controlled energy delivery to quickly create strong vessel seals. The EnSeal(R) device, cleared by the FDA in 2003, is capable of sealing vessels up to 7mm in diameter.

About Ethicon Endo-Surgery

Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at www.ethiconendo.com.

More Voices